CTLA4 and melanoma: At present, there are three classes of therapies approved for melanoma, the alkylating agents such as dacarbazine, the targeted therapies such as the selective inhibitor of BRAF V600E, and immunotherapeutic agents including anti-CTLA-4 antibody and more recently anti-PD-1 antibody (43).